Terms: = Kidney tumors AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C AND Treatment
4 results:
1. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
2. Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab treatment in Patients with Advanced Renal Cell Carcinoma.
Martini JF; Plimack ER; Choueiri TK; McDermott DF; Puzanov I; Fishman MN; Cho DC; Vaishampayan U; Rosbrook B; Fernandez KC; Tarazi JC; George S; Atkins MB
Clin Cancer Res; 2020 Nov; 26(21):5598-5608. PubMed ID: 32816890
[TBL] [Abstract] [Full Text] [Related]
3. [Production and identification of a monoclonal antibody against a tumor associated antigen from ovarian epithelial carcinoma].
Gong GL; Zou JY; Cai ZT
Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):395-7, 443-4. PubMed ID: 8001414
[TBL] [Abstract] [Full Text] [Related]
4. Production and characterization of mouse monoclonal antibodies to human bladder tumor-associated antigens.
Young DA; Prout GR; Lin CW
Cancer Res; 1985 Sep; 45(9):4439-46. PubMed ID: 3896480
[TBL] [Abstract] [Full Text] [Related]
